Jan 16, 2026
What are the common side effects and monitoring requirements for lecanemab and donanemab?
Lecanemab and donanemab are monoclonal anti‑amyloid antibodies approved for early Alzheimer’s disease that produce modest slowing of decline but carry important and common safety risks—most notably am...